Brain Cancer Diagnostics Market it is estimated to grow at a CAGR of 28.5%

1. Brain Cancer Diagnostics Market Global Analysis and Forecast to 2028 Published Date : Jun 2022 Email: sales@theinsightpartners.com

2. Email:sales@theinsightpartners.com Report Studies • Brain Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnostic Type (Imaging Test [MRI, CT Scan, PET, and Others], Lumbar Puncture, Biopsy, Molecular Testing, Platform and Services [Sample Slide, Autosampler Unit, Solutions & Platform, and Services], Cerebral Arteriogram, Neurological & Hearing Tests/Neurocognitive Assessments, Electroencephalography (EEG), and Others); Cancer Type (Acoustic Neuroma, Astrocytomas, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas, Oligodendroglioma, Low-Grade Tumors, and Others); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Diagnostic Centers & Research Institutes, and Others); and Tumor Size (0.2 cm3 to 100 cm3, 101 cm3 to 200 cm3, and Above 200 cm3)

3. Email:sales@theinsightpartners.com Brain Cancer Diagnostics Market Value CAGR of 3.8% (2022 - 2028)

4. Email:sales@theinsightpartners.com Brain Cancer Diagnostics Market Overview • The brain cancer diagnostics market is projected to reach US$ 7,378.57 Million by 2028 from US$ 1,639.10 Million in 2022; it is estimated to grow at a CAGR of 28.5% from 2022 to 2028. • Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

5. Email:sales@theinsightpartners.com Key Segment Market Segment By Type:- • By Diagnostic Type (Imaging Test [MRI, CT Scan, PET, and Others], Lumbar Puncture, Biopsy, Molecular Testing, Platform and Services [Sample Slide, Autosampler Unit, Solutions & Platform, and Services], Cerebral Arteriogram, Neurological & Hearing Tests/Neurocognitive Assessments, Electroencephalography (EEG), and Others) • By Cancer Type (Acoustic Neuroma, Astrocytomas, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas, Oligodendroglioma, Low-Grade Tumors, and Others) • End End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Diagnostic Centers & Research Institutes, and Others) • Tumor Size (0.2 cm3 to 100 cm3, 101 cm3 to 200 cm3, and Above 200 cm3)

6. Email:sales@theinsightpartners.com Company Profiles • THERMO FISHER SCIENTIFIC INC • Siemens Healthineers AG • GE Healthcare • MDxHealth • NantOmics • Biocept, Inc. • Koninklijke Philips N.V. • Canon Medical Systems • Hitachi, Ltd • Neusoft Medical Systems • KITZ HEIDELBERG Download Sample Here

7. Email:sales@theinsightpartners.com By Geography • North America (the US, Canada, and Mexico) • Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe) • Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific) • Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa) • South & Central America (Brazil, Argentina, and the Rest of South & Central America).

8. THANKYOU! Phone : +1-646-491-9876 E-Mail : sales@theinsightpartners.com